George Gabriel, DO
Cardiovascular Disease · Pittsburgh, PANPI 1235139585
Payments from drug & device makers
Across 1,104 payments — averaging $528.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$168K
- Amgen$119K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$111K
- Lilly USA, LLC$75K
- AstraZeneca$34K
- E.r. Squibb & Sons, L.L.C.$27K
- plus $49K from 29 others
What the payments were for
- Consulting fees$6,6381%
- Speaking & faculty fees$515,03192%
- Travel & lodging$6,8441%
- Food & beverage$34,0016%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 189 | $168,093 |
| Amgen(2 entities) | 156 | $119,251 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 204 | $110,980 |
| Lilly USA, LLC | 90 | $75,343 |
| AstraZeneca | 45 | $33,861 |
| E.r. Squibb & Sons, L.L.C. | 85 | $27,039 |
| Boston Scientific | 36 | $20,870 |
| Pfizer | 61 | $19,810 |
| Medtronic | 82 | $3,044 |
| Novartis | 44 | $1,932 |
| Heartflow, Inc. | 15 | $534 |
| Impulse Dynamics (USA) Inc. | 11 | $457 |
| Novo Nordisk | 15 | $400 |
| Johnson & Johnson | 16 | $323 |
| Cvrx, Inc. | 19 | $277 |
| Abiomed | 4 | $260 |
| Edwards Lifesciences | 2 | $237 |
| Stryker | 1 | $168 |
| Inari Medical, Inc. | 1 | $152 |
| Esperion Therapeutics, Inc. | 2 | $152 |
| Altathera Pharmaceuticals LLC | 4 | $98 |
| Amarin Pharma, Inc. | 5 | $80 |
| Bayer | 3 | $67 |
| Lexicon Pharmaceuticals, Inc. | 2 | $63 |
| Abbott | 2 | $57 |
| Kestra Medical Technology Services, Inc. | 1 | $27 |
| Cook Medical LLC | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| GE HealthCare | 1 | $22 |
| Chiesi USA, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Shockwave Medical, Inc | 1 | $16 |
| Getinge USA Sales, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$222,535
- LifeVest$104,160
- Repatha$95,333
- ELIQUIS$43,638
- FARXIGA$33,494
- WATCHMAN Access System$19,461
- TRULICITY$17,598
- LEQVIO$1,188
- Watchman$681
- ONYX FRONTIER$208
- WATCHMAN FLX$183
- VENACORE THROMBECTOMY CATHETER$168
- FLOWTRIEVER CATHETER, S$152
- CT THROMBECTOMY SYSTEM KIT$152
- Impella$137
- SAPIEN 3 Ultra RESILIA$133
- XARELTO$129
- NEXLIZET$125
- NEXLETOL$125
- Wegovy$124
How this compares
$583,758 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 72 | $76,047 |
| Repatha SureclickEvolocumab | 57 | $36,327 |
| EntrestoSacubitril/Valsartan | 16 | $20,829 |
| JardianceEmpagliflozin | 19 | $17,884 |
| XareltoRivaroxaban | 11 | $5,794 |
| Ranolazine ErRanolazine | 27 | $2,583 |
| Metoprolol Succinate | 69 | $892 |
| Potassium Chloride | 24 | $888 |
| Rosuvastatin Calcium | 44 | $873 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 50 | $807 |
| Bumetanide | 18 | $704 |
| Valsartan | 30 | $692 |
| Ezetimibe | 41 | $690 |
| Losartan Potassium | 28 | $565 |
| Warfarin Sodium | 61 | $541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $19,810 | $76,04772 claims |
| NovartisEntresto | $1,932 | $20,82916 claims |
| Boehringer IngelheimJardiance | $168,093 | $17,88419 claims |
| Johnson & JohnsonXarelto | $323 | $5,79411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Pittsburgh
- Stephen ChanPittsburgh$1.2M
- Rewat CholapraneePittsburgh$598K
- Indu PoornimaPittsburgh$422K
- Brian HenryPittsburgh$269K
- Timothy WongPittsburgh$265K
- Mark GreathousePittsburgh$243K
- Danielle DuffyPhiladelphia$29.5M
- Venkatesh NadarCamp Hill$18.3M
- Hemal GadaWormleysburg$6.7M
- Brian DrachmanPhiladelphia$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.